Orphan designation: canvuparatide Treatment of hypoparathyroidism, 09/01/2026 Positive
Orphan designation: human IgG1 kappa monoclonal antibody against pappalysin-1 Treatment of autosomal dominant polycystic kidney disease, 09/01/2026 Positive
Orphan designation: navtemadlin Treatment of myelofibrosis, 09/01/2026 Positive
Orphan designation: saracatinib Treatment of fibrodysplasia ossificans progressiva, 09/01/2026 Positive
Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 72, Status: Authorised
Orphan designation: alpibectir,ethionamide Treatment of tuberculosis Positive
Orphan designation: surovatamig Treatment of follicular lymphoma, 09/01/2026 Positive
Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Date of authorisation: 14/02/2019, Revision: 19, Status: Authorised
Records of data processing activity on processing of personal data pertaining to staff absence
HMPC meeting report on European Union herbal monographs, guidelines and other activities - 2-4 March 2026